Cecilia L. Moore

719 citations

20 papers · 434 indexed · h-index 12

Co-authors: Sean Emery Janaki Amin Mark Boyd Jean‐Michel Molina Hedy Teppler Allison Martin Matthew Law Lerato Mohapi
Topics: HIV/AIDS drug development and treatment (13 papers)HIV Research and Treatment (11 papers)HIV-related health complications and treatments (9 papers)
Cited by: Virology Infectious Diseases Emergency Medicine
Journals: The Lancet PLoS ONE Journal of Clinical Epidemiology
Partner nations: Australia France Thailand

In The Last Decade

Cecilia L. Moore

20 papers receiving 425 citations

Peers

Countries citing papers authored by Cecilia L. Moore

Since Specialization

Citations

This map shows the geographic impact of Cecilia L. Moore's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Cecilia L. Moore with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Cecilia L. Moore more than expected).

Fields of papers citing papers by Cecilia L. Moore

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Cecilia L. Moore. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Cecilia L. Moore. The network helps show where Cecilia L. Moore may publish in the future.

Co-authorship network of co-authors of Cecilia L. Moore

This figure shows the co-authorship network connecting the top 25 collaborators of Cecilia L. Moore. A scholar is included among the top collaborators of Cecilia L. Moore based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Cecilia L. Moore. Cecilia L. Moore is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Mental health and wellbeing coordinators in primary schools to support student mental health: protocol for a quasi-experimental cluster study 2021 ·BMC Public Health ·(unknown),(unknown),Jon Quach,Rachel Smith,(unknown),(unknown),(unknown),Cecilia L. Moore,Jemimah Ride,Frank Oberklaid	18
2	Simplified dolutegravir dosing for children with HIV weighing 20 kg or more: pharmacokinetic and safety substudies of the multicentre, randomised ODYSSEY trial 2020 ·The Lancet HIV ·(unknown),Cecilia L. Moore,Hilda Mujuru,Shafic Makumbi,Adeodata Kekitiinwa,(unknown),Anna Parker,Godfrey Musoro,(unknown),Abbas Lugemwa,Pauline Amuge,James Hakim,Pablo Rojo,Carlo Giaquinto,Angela Colbers,Diana M. Gibb,Deborah Ford,Anna Turkova,David M. Burger	21
3	Multi-arm, multi-stage randomised controlled trials for evaluating therapeutic HIV cure interventions 2019 ·The Lancet HIV ·Cecilia L. Moore,Wolfgang Stöhr,Angela M. Crook,Laura Richert,Jean‐Daniel Lelièvre,Giuseppe Pantaleo,Felipe García,Stefano Vella,(unknown),Rodolphe Thiébaut,Sheena McCormack	6
4	Relationship between untimed plasma lopinavir concentrations and virological outcome on second-line antiretroviral therapy 2018 ·AIDS ·(unknown),Cecilia L. Moore,Dianne Carey,Janaki Amin,(unknown),Marcelo Losso,P.L. Lim,Lerato Mohapi,Jean‐Michel Molina,Brian Gazzard,David A. Cooper,Mark Boyd	3
5	Metabolic Profiles of Individuals Switched to Second-Line Antiretroviral Therapy after Failing Standard First-Line Therapy for Treatment of HIV-1 Infection in a Randomized, Controlled Trial 2017 ·Antiviral Therapy ·(unknown),Cecilia L. Moore,Poh Lian Lim,Jean‐Michel Molina,Juan Sierra Madero,Stephen J. Kerr,Patrick Mallon,Sean Emery,David A. Cooper,Mark Boyd,(unknown)	2
6	Poor record linkage sensitivity biased outcomes in a linked cohort analysis 2016 ·Journal of Clinical Epidemiology ·Cecilia L. Moore,Heather F. Gidding,Matthew Law,Janaki Amin	9
7	Antiretroviral Resistance After First-Line Antiretroviral Therapy Failure in Diverse HIV-1 Subtypes in the SECOND-LINE Study 2016 ·AIDS Research and Human Retroviruses ·(unknown),Cecilia L. Moore,Eduardo Gotuzzo,(unknown),Adeeba Kamarulzaman,Ploenchan Chetchotisakd,Jean van Wyk,Hedy Teppler,Nagalingeswaran Kumarasamy,Jean‐Michel Molina,Sean Emery,David A. Cooper,Mark Boyd,(unknown)	12
8	Body composition and metabolic outcomes after 96 weeks of treatment with ritonavir-boosted lopinavir plus either nucleoside or nucleotide reverse transcriptase inhibitors or raltegravir in patients with HIV with virological failure of a standard first-line antiretroviral therapy regimen: a substudy of the randomised, open-label, non-inferiority SECOND-LINE study 2016 ·The Lancet HIV ·Mark Boyd,Janaki Amin,Patrick Mallon,Nagalingeswaran Kumarasamy,Johan Lombaard,Robin Wood,Ploenchan Chetchotisakd,Praphan Phanuphak,Lerato Mohapi,Iskandar Azwa,Waldo Belloso,Jean‐Michel Molina,Jennifer Hoy,Cecilia L. Moore,Sean Emery,David A. Cooper	5
9	Patterns of Drug Use and Drug-related Hospital Admissions in HIV-Positive and -Negative Gay and Bisexual Men 2016 ·AIDS and Behavior ·Cecilia L. Moore,Heather F. Gidding,Fengyi Jin,Limin Mao,Kathy Petoumenos,Iryna Zablotska,I. Mary Poynten,Garrett Prestage,Matthew Law,Andrew E. Grulich,Janaki Amin	9
10	Hospitalization for Anxiety and Mood Disorders in HIV-Infected and -Uninfected Gay and Bisexual Men 2016 ·JAIDS Journal of Acquired Immune Deficiency Syndromes ·Cecilia L. Moore,Andrew E. Grulich,Garrett Prestage,Heather F. Gidding,Fengyi Jin,Kathy Petoumenos,Iryna Zablotska,I. Mary Poynten,Limin Mao,Matthew Law,Janaki Amin	9
11	Raltegravir Non-Inferior to Nucleoside Based Regimens in SECOND-LINE Therapy with Lopinavir/Ritonavir over 96 Weeks: A Randomised Open Label Study for the Treatment Of HIV-1 Infection 2015 ·PLoS ONE ·Janaki Amin,Mark Boyd,Nagalingeswaran Kumarasamy,Cecilia L. Moore,M Losso,(unknown),Lerato Mohapi,Stephen J. Kerr,Annette H. Sohn,Hedy Teppler,Boris Renjifo,Jean‐Michel Molina,Sean Emery,David A. Cooper	31
12	Baseline HIV-1 resistance, virological outcomes, and emergent resistance in the SECOND-LINE trial: an exploratory analysis 2015 ·The Lancet HIV ·Mark Boyd,Cecilia L. Moore,Jean‐Michel Molina,Robin Wood,Juan Sierra Madero,Marcelo Wolff,Kiat Ruxrungtham,Marcelo Losso,Boris Renjifo,Hedy Teppler,Anthony D. Kelleher,Janaki Amin,Sean Emery,David A. Cooper	63
13	Hospitalisation rates and associated factors in community‐based cohorts of HIV‐infected and ‐uninfected gay and bisexual men 2015 ·HIV Medicine ·Cecilia L. Moore,AE Grulich,Garrett Prestage,Heather F. Gidding,Fengyi Jin,Limin Mao,Kathy Petoumenos,(unknown),(unknown),Matthew Law,Janaki Amin	5
14	Early antiretroviral therapy with raltegravir generates sustained reductions in HIV reservoirs but not lower T-cell activation levels 2015 ·AIDS ·(unknown),John M. Murray,Ven Natarajan,Janaki Amin,Cecilia L. Moore,Sean Emery,David A. Cooper,John Zaunders,Anthony D. Kelleher,Kersten K. Koelsch	31
15	A New Method for Assessing How Sensitivity and Specificity of Linkage Studies Affects Estimation 2014 ·PLoS ONE ·Cecilia L. Moore,Janaki Amin,Heather F. Gidding,Matthew Law	28
16	Bone Mineral Density Over 96 Weeks in Adults Failing First-Line Therapy Randomized to Raltegravir/Lopinavir/Ritonavir Compared With Standard Second-Line Therapy 2014 ·JAIDS Journal of Acquired Immune Deficiency Syndromes ·Hila Haskelberg,Patrick Mallon,Jennifer Hoy,Janaki Amin,Cecilia L. Moore,Praphan Phanuphak,Samuel Ferret,Waldo Belloso,Mark Boyd,David A. Cooper,Sean Emery	12
17	HIV Lipodystrophy in Participants Randomised to Lopinavir/Ritonavir (LPV/r) +2–3 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors (N(t)RTI) or LPV/r + Raltegravir as Second-Line Antiretroviral Therapy 2013 ·PLoS ONE ·Allison Martin,Cecilia L. Moore,Patrick Mallon,Jennifer Hoy,Sean Emery,Waldo Belloso,Praphan Phanuphak,Samuel Ferret,David A. Cooper,Mark Boyd,(unknown)	14
18	Ritonavir-boosted lopinavir plus nucleoside or nucleotide reverse transcriptase inhibitors versus ritonavir-boosted lopinavir plus raltegravir for treatment of HIV-1 infection in adults with virological failure of a standard first-line ART regimen (SECOND-LINE): a randomised, open-label, non-inferiority study 2013 ·The Lancet ·(unknown),Mark Boyd,Nagalingeswaran Kumarasamy,Cecilia L. Moore,(unknown),M Losso,Lerato Mohapi,Allison Martin,Stephen J. Kerr,(unknown),Hedy Teppler,(unknown),Jean‐Michel Molina,Sean Emery	109
19	Bone mineral density in HIV participants randomized to raltegravir and lopinavir/ritonavir compared with standard second line therapy 2013 ·AIDS ·Allison Martin,Cecilia L. Moore,Patrick Mallon,Jennifer Hoy,Sean Emery,Waldo Belloso,Praphan Phanuphak,Samuel Ferret,David A. Cooper,Mark Boyd	32
20	Protease inhibitors and nucleoside analogue reverse transcriptase inhibitors interact to cause subcutaneous fat wasting in patients with HIV infection 1999 ·Murdoch Research Repository (Murdoch University) ·S. Mallal,Mina John,Cecilia L. Moore,Ian James,E. McKinnon	15

About Cecilia L. Moore

Cecilia L. Moore is a scholar working on Virology, Emergency Medicine and Infectious Diseases, having authored 20 papers that have together received 434 indexed citations. Recurring topics across this work include HIV/AIDS drug development and treatment (13 papers), HIV Research and Treatment (11 papers) and HIV-related health complications and treatments (9 papers). The work is most often cited by research in Virology (250 citations), Infectious Diseases (310 citations) and Emergency Medicine (128 citations). Cecilia L. Moore has collaborated with scholars based in Australia, France and Thailand. Frequent co-authors include Sean Emery, Janaki Amin, Mark Boyd, Jean‐Michel Molina, Hedy Teppler, Allison Martin, Matthew Law, Lerato Mohapi, Heather F. Gidding and M Losso. Their work appears in journals such as The Lancet, PLoS ONE and Journal of Clinical Epidemiology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact